Key result
Solifenacin suppresses coronary arterial Kv currents at ~15 μM by modulating Kv1.5 inactivation gating.
Why the study?
Several muscarinic receptor antagonists modulate vascular voltage-dependent K+ channels, but the electrophysiological effects of solifenacin on these channels have not been fully characterized.
Does solifenacin modulate voltage-dependent K+ channel activity in native coronary arterial smooth muscle cells?
Does solifenacin modulate voltage-dependent K+ channel activity in native coronary arterial smooth muscle cells?
Solifenacin directly inhibits vascular Kv channels in a concentration- and state-dependent manner, independent of its antimuscarinic activity, highlighting a potential off-target effect on coronary vascular tone.
Should not yet change practice; hypothesis-generating for solifenacin effects on coronary vascular tone.
Several muscarinic receptor antagonists have been reported to modulate vascular voltage-dependent K + (Kv) channels; however, the electrophysiological effects of solifenacin on these channels have not been fully characterized.We used the whole-cell patch-clamp technique to examine the effects of solifenacin on Kv currents in rabbit coronary arterial smooth muscle cells.Solifenacin suppressed arterial Kv currents in a concentration-dependent manner, with half-maximal inhibitory concentration (IC 50 ) of 14.59 ± 4.78 μM and a Hill coefficient of 0.84 ± 0.15.Although 30 μM solifenacin did not significantly affect steady-state activation, it produced a pronounced leftward shift in the steady-state inactivation curve.These findings imply that solifenacin inhibits Kv channels through interaction with the inactivation gating machinery.Consistent with this interpretation, solifenacin displayed use (state)-dependent inhibition: repetitive stimulation at 1 Hz progressively reduced current amplitude, and the recovery time constant from inactivation was significantly prolonged.To determine the Kv subtypes involved, subtype-selective inhibitors were applied.The inhibitory effect of solifenacin was not significantly modified by the Kv2.1 inhibitor stromatoxin-1 or the Kv7 inhibitor linopirdine.By contrast, pretreatment with the Kv1.5 inhibitor DPO-1 partially attenuated inhibition of peak currents but had minimal effect on steady-state inhibition.These results indicate that solifenacin targets multiple Shaker-related (Kv1.x)channel subtypes, with Kv1.5 making a substantial contribution to the observed current suppression.Solifenacin inhibits arterial Kv channels in a concentration-and use (inactivated state)-dependent manner by modulating inactivation gating, predominantly involving the Kv1.5 subtype.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied None (Healthy rabbit coronary arterial smooth muscle cells). Solifenacin vs. Control (absence of solifenacin) was evaluated on Inhibition of steady-state Kv currents (IC50 14.59 ± 4.78 μM). Solifenacin suppressed coronary arterial voltage-dependent K+ currents in a concentration-dependent manner with an IC50 of 14.59 μM, primarily by modulating inactivation gating of the Kv1.5 subtype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: